Hamlin Capital Management, LLC, a registered investment adviser, initiated a new position in AbbVie Inc. (NYSE:ABBV) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 935,184 shares of the Healthcare company, valued at approximately $213,680,192 as of the filing date.
AbbVie Inc.'s stock currently trades at $233.43 with a market capitalization of $395,662,263,610.